Cold Plasma for the Reduction of Lymphoceles Following PLND
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02658851 |
Recruitment Status :
Completed
First Posted : January 20, 2016
Results First Posted : December 2, 2020
Last Update Posted : December 2, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Lymphoceles Following Pelvic Lymph Node Dissection | Device: J-Plasma | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 100 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Application of Cold Plasma Energy for Reduction of Lymphoceles Following Pelvic Lymph Node Dissection During Robot-Assisted Radical Prostatectomy |
Study Start Date : | June 2016 |
Actual Primary Completion Date : | June 27, 2017 |
Actual Study Completion Date : | June 27, 2017 |
Arm | Intervention/treatment |
---|---|
Experimental: J-Plasma
Enrolled participants will have their PLND performed using J-Plasma® for dissection and sealing of lymphatic channels.
|
Device: J-Plasma
Bovie Medical Corporation's J-Plasma® helium based plasma technology is a hemostatic tool for the cutting, coagulation, and ablation of soft tissue.
Other Name: Cold plasma |
- Number of Participants With Incidence of Lymphocele Formation [ Time Frame: 12 weeks ]The primary outcome to be measured will be the incidence of lymphocele formation as diagnosed upon post- operative abdominal ultrasound.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Primary diagnosis of Prostate Cancer (ICD-10:C61)
- Prostate Specific Antigen (PSA) level =/> 10ng/mL
- Gleason score =/> 7
- Planned Elective Robotic Assisted Radical Prostatectomy with planned pelvic lymph node dissection.
- Willing and able to return to clinic for standard of care abdominal ultrasound within 12 weeks post operatively.
- Able to provide informed consent
Exclusion Criteria:
Must answer no to all:
- Patient is unwilling or unable to sign or understand informed consent
- Patient resides outside of the United States
- Performance of Lymph node dissection was aborted.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02658851
United States, Florida | |
Florida Hospital Global Robotics Institute | |
Celebration, Florida, United States, 34747 |
Principal Investigator: | Vipul R Patel, MD | Florida Hospital Global Robotics Institute |
Responsible Party: | Apyx Medical |
ClinicalTrials.gov Identifier: | NCT02658851 |
Other Study ID Numbers: |
808076 |
First Posted: | January 20, 2016 Key Record Dates |
Results First Posted: | December 2, 2020 |
Last Update Posted: | December 2, 2020 |
Last Verified: | December 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | No |
lymphocele pelvic lymph node dissection robotic assisted radical prostatectomy PLND |
RARP prostatectomy Patel |
Lymphocele Cysts Neoplasms Lymphatic Diseases |